14:05:37 EDT Sat 26 Sep 2020
Enter Symbol
or Name

Login ID:
Ravenquest Biomed Inc
Symbol RQB
Shares Issued 123,913,559
Close 2020-01-09 C$ 0.11
Recent Sedar Documents

ORIGINAL: Ravenquest acquires digital pot education company

2020-01-10 10:55 ET - News Release

Received by email:

File: Attachment RQB-NR-Digigro Acquisition.pdf

                         ACQUISITION OF DIGIGRO

NR19-                                                                                    Jaunary 10, 2020

January 10, 2020   Vancouver, British Columbia   RavenQuest BioMed Inc. (CSE: RQB OTCQB:
RVVQF Frankfurt: 1IT) (the "Company" or "RavenQuest"), Canada's leading cannabis technology
innovator, today announced the acquisition of Digigro, a ground breaking digital platform providing home
growers access to best-in-class cultivation knowledge and techniques.

Digigro will connect the home-grower of personal-use cannabis to AI-based knowledge of the best-in-
class cultivation techniques and supplies at no charge. Using a single platform, the app will assemble data
collected from home-growers and will thereupon provide information that will allow them to produce the
best cannabis with the fewest negative outcomes.

The grower will provide the input data by selecting their preferred cultivar and the app will subsequently
offer relevant information for optimal growing conditions such as preferred nutrients, substrates, ideal
feeding cycles and optimal lighting conditions.

Currently, consumers do not have the luxury of a single, reliable resource that assists them with the
rewarding but often challenging experience of home-growing cannabis. Digigro will be the answer to this

Digigro will be commercialized by allowing the purchase of advertisement space by product vendors and
suppliers as well as a future e-commerce platform for the direct shipment of various products from vendor
to home-grower.

RavenQuest CEO, George Robinson, commented "as we transition to a technology focused company this
will provide a new source of revenue. As we move toward a broader and more diversified revenue model,
this transaction makes excellent sense as our company drives cannabis-related revenue outside of simply
plant or extract sales."

RavenQuest will issue [shares here] as consideration for the transaction.

For more information, access RavenQuest's investor presentation, fact sheet and videos here.

Follow RavenQuest:

About RavenQuest BioMed Inc.

                                          RavenQuest BioMed Inc.
                           Suite 780   580 Hornby Street, Vancouver, BC, V6C 3B6
                                         Phone/Fax: 1-877-282-1586
 RavenQuest Biomed Inc.                                 2                                     October 18, 2019
NR19-23 Continued

RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized research & development. RavenQuest is a
licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain)
recognition, plant stabilization and yield maximization of the cannabis plant. The Company also focuses
on partnerships with Indigenous communities.

On Behalf of the Board of Directors of

"George Robinson"
Chief Executive Officer

For further information, please contact: Mathieu McDonald, Corporate Communications

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in
the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of
this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are "forward-looking
information" with respect to the Company within the meaning of applicable securities laws. The Company
provides forward-looking statements for the purpose of conveying information about current expectations
and plans relating to the future and readers are cautioned that such statements may not be appropriate for
other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be
general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections
or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives,
strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited
those identified and reported in the Company's public filings under the Company's SEDAR profile at
www.sedar.com. Although the Company has attempted to identify important factors that could cause actual
actions, events or results to differ materially from those described in forward-looking information, there
may be other factors that cause actions, events or results not to be as anticipated, estimated or intended.
There can be no assurance that such information will prove to be accurate as actual results and future events
could differ materially from those anticipated in such statements. The Company disclaims any intention or
obligation to update or revise any forward-looking information, whether as a result of new information,
future events or otherwise unless required by law.

                                           RavenQuest BioMed Inc.
                            Suite 780   580 Hornby Street, Vancouver, BC, V6C 3B6
                                          Phone/Fax: 1-877-282-1586

© 2020 Canjex Publishing Ltd. All rights reserved.